Follow Michael A Robinson Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The coronavirus panic has most of the economy in a deep freeze.
Brick-and-mortar retail stores are getting hammered. (The U.S. Commerce Department says retail sales for March fell a seasonally adjusted 8.7% — the biggest one-month decline since it started keeping records in 1992.)
We're seeing other stressors in the food supply chain.
Unemployment is spiking.
And the U.S. economy is headed for a recession.
This spiraling storm is changing the corporate landscape, is widening the gap between the winners and losers, and is changing the opportunity matrix for investors.
And the COVID-19 pandemic is transforming one heavyweight into an absolute juggernaut.
I'm talking about Amazon.com Inc. (NASDAQ: AMZN), the King of E-Commerce, which has become the essential retailing icon of the pandemic.
Today I'm here to make a prediction.
And to answer a question.
Amazon is currently trading at about $2,350 a share.
That's more than five times where it was five years ago – a fact that has lots of investors asking: "Is it too late to buy Amazon?"
Absolutely not.
In fact, I'm predicting we'll eventually see Amazon at $3,000 a share as a result of the market and mindshare gains the company has made during this crisis. And the stock will move higher from there.
Today I'm going to show you why…
Responding to the Times
I think it's safe to say that Amazon is an elite company – and an elite stock. It boasts a market cap of nearly $1.2 trillion.
More to the point, it has performed better in this market than two other $1 trillion market value companies. Both Microsoft Corp. (NASDAQ: MSFT), valued at $1.3 trillion, and Apple Inc. (NASDAQ: AAPL), valued at $1.2 trillion, remain off their recent highs.
Amazon recently hit a closing high of $2,400. The bellwether Standard & Poor's 500 Index closed at just about breakeven that same day, by contrast, and on that same day was still down off just shy of 18% since hitting its high on Feb. 19.
And it's not just its other high-tech peers that Amazon is besting.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.